SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (471)12/27/1999 4:30:00 PM
From: tnsaf  Respond to of 52153
 
Hmm, they are both up about 10X from low to high and their charts look awfully similar. On market cap basis, though, MEDX is half ABGX.

Jason



To: Biomaven who wrote (471)12/27/1999 6:23:00 PM
From: RWReeves  Read Replies (1) | Respond to of 52153
 
Medx Seems to have been quietly moving along.

Using Bigcharts:

bigcharts.com

You can add PDLI or ABGX and compare. Timeframe is important as to which is the more "overvalued" <g>.
If you take it out a year, MEDX seems to be up 900% on the recent spike, a near 10 bagger that somehow evaded my scope. At 6 months ABGX is the top runner.

Interesting licensing situation as I read more about it.

RWR


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News